| 1.28 -0.01 (-0.78%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.61 | 1-year : | 1.77 |
| Resists | First : | 1.38 | Second : | 1.51 |
| Pivot price | 1.27 |
|||
| Supports | First : | 1.15 | Second : | 0.96 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.27  |
| MA(100) : | 1.39 |
MA(250) : | 2.32 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.8 |
D(3) : | 26.1 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 8.81 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIXC ] has closed below upper band by 46.0%. Bollinger Bands are 63% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.24 - 1.24 | 1.24 - 1.25 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Sat, 06 Jun 2026
AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: EAI Infrastructure Strategic Partnership - Quantisnow
Mon, 01 Jun 2026
Number of shareholders of AIxCrypto Holdings, Inc. – NASDAQ:AIXC - TradingView
Thu, 28 May 2026
Executive shake-up as AIxCrypto (NASDAQ: AIXC) winds down biotech business - Stock Titan
Thu, 14 May 2026
AIxCrypto (NASDAQ: AIXC) exits Marizyme loan for cash, royalties and equity - Stock Titan
Mon, 11 May 2026
AIxCrypto (Nasdaq: AIXC) Q1 2026 loss, cash burn and Faraday investment - Stock Titan
Wed, 25 Mar 2026
AIxCrypto Holdings Inc (AIXC) Q4 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 20 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 78 (K) |
| Shares Short P.Month | 116 (K) |
| EPS | -7.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.75 |
| Profit Margin | 0 % |
| Operating Margin | -382.2 % |
| Return on Assets (ttm) | -42.6 % |
| Return on Equity (ttm) | -237 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | -1.71 |
| Price to Sales | 6 |
| Price to Cash Flow | -2.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|